In the fast-growing nutraceutical industry, scientific validation has become a decisive differentiator. Brands must now combine robust evidence, regulatory compliance, and high-performing ingredients to deliver products that meet the expectations of increasingly informed consumers.

This article explores the main types of efficacy studies and how innovative, science-backed ingredients—highlighted through our collaboration with Evonik—can help you design credible and high-impact nutraceutical formulas.

Choosing the Right Ingredient Strategy

The choice of active ingredients depends on the desired market positioning, investment capacity, and long-term vision of your brand.

• For cost-sensitive formulations, a combination of actives supported by literature reviews and preliminary in-vitro data may be sufficient.
• For premium or science-driven products, investing in ingredients supported by in-vivo and clinical research becomes essential to secure regulatory compliance and market trust.

In-Vitro Studies: The Scientific Foundation

In-vitro studies form the first level of scientific substantiation. Conducted in controlled settings using isolated cells or tissues, they provide early insights into a compound’s biological activity.
For instance, an in-vitro study may evaluate how a plant sterol interferes with cholesterol synthesis in liver cells. While these results are valuable for screening and hypothesis building, in-vitro findings alone are not sufficient to support nutraceutical health claims.

In-Vivo Studies: Understanding Biological Complexity

In-vivo studies deepen scientific understanding by evaluating effects in whole organisms, typically animal models. They clarify bioavailability, metabolism, safety, and systemic activity. Although in-vivo results better reflect physiological realities, they still require careful interpretation and cannot be directly generalized to humans.

Clinical Studies: The Pinnacle of Proof

Clinical research is the highest level of evidence. Randomized controlled trials (RCTs) generate robust data on safety and efficacy and are considered essential for substantiating health claims according to regulators such as FDA and EFSA.
A typical example would be an RCT measuring the impact of fish oil on triglyceride levels in people with hyperlipidemia. These data points significantly influence consumer trust and product acceptance.

As regulatory frameworks evolve, scientific expectations rise. The 2023 opening of probiotics-related claims in France illustrates how new opportunities emerge for companies prepared to invest in evidence-based innovation.

Co-Branding: Strengthening Market Credibility

Co-branding is an increasingly strategic tool for nutraceutical companies. By partnering with suppliers known for scientific rigor, brands can:

• Leverage shared expertise
• Strengthen product credibility
• Improve regulatory compliance
• Accelerate market adoption

Safic-Alcan collaborates closely with innovation-driven partners such as Evonik, whose work on next-generation synbiotics is reshaping the category.

Expert Insights with Evonik: Innovations Powered by Data

We spoke with Dr. Bodo Speckmann, Health Science & Technology Lead at Evonik’s business incubator Creavis, to explore how scientific and technological innovation shapes modern nutraceutical development.

Evonik’s Strategy: Science as a Differentiator

According to Dr. Speckmann, the nutraceutical market is shifting toward proven, convenient, and science-backed solutions. Evonik focuses on areas with high consumer demand—cardiovascular, cognitive, and gut health—while developing a groundbreaking new category: IN VIVO BIOTICS™, synbiotics that convert specific ingredients into bioactive compounds directly in the intestine.

These solutions use advanced probiotics and complementary bioactives to support preventative and adjuvant nutrition—contributing to Evonik’s global sustainability efforts and long-term health commitments.

Case Study: IN VIVO BIOTICS™ Gluten Tolerance

A recent innovation illustrates this science-driven approach. Individuals with gluten sensitivity often struggle with solutions that lack efficacy or practicality. Evonik addressed this gap by studying the role of the gut microbiome and identifying strains capable of fast and complete gluten degradation.

The resulting synbiotic uses:

• Probiotic strains with complementary enzyme production
• Microbial lysates for immediate action
• Viable strains for long-term engraftment

The dual mechanism enables both acute and persistent efficacy. IN VIVO BIOTICS™ gluten tolerance is currently undergoing an RCT to assess its role as an adjuvant nutritional intervention for people with celiac disease.

Supporting Customers Beyond Ingredients

Evonik also provides:

• Formulation expertise
• Regulatory guidance
• Support for compliant health benefit communication
• Deep market and consumer insight

This ensures customers can move confidently from concept to market-ready products with clear scientific backing.

Conclusion

Evidence-based innovation is now the foundation of successful nutraceutical product development. By understanding the hierarchy of scientific studies, navigating the evolving regulatory landscape, and collaborating with partners committed to data-driven excellence, companies can build formulations that truly perform to convince.

Safic-Alcan and its partners, including Evonik, stand ready to support your next generation of science-backed nutraceutical solutions.